Journals / Üroonkoloji Bülteni / 2021 / Cilt: 20 - Sayı: 1

Predictive Value of Duration and Frequency of Macroscopic Haematuria for Stage, Prognosis and Recurrence in Bladder Cancer Patients

Pages
34–39
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No significant relationships were observed between the duration of haematuria and cancer recurrence rates and prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to investigate the predictive value of duration and frequency of macroscopic haematuria for the stage, prognosis and recurrence rates in primary bladder cancer.
📊
Key Findings & Data:Materials and Methods: We retrospectively reviewed the data of our patients diagnosed with primary bladder cancers during 2000-2014.
💡
Conclusion & Impact:No significant relationships were observed between the duration of haematuria and cancer recurrence rates and prognosis.
🔬Design:Review & Systematic Survey
📍Scope:2000-2014 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: We aimed to investigate the predictive value of duration and frequency of macroscopic haematuria for the stage, prognosis and recurrence rates in primary bladder cancer. Materials and Methods: We retrospectively reviewed the data of our patients diagnosed with primary bladder cancers during 2000-2014. Patients with history of macroscopic haematuria were included. Their haematuria duration and frequency and stage and grade of bladder cancer, recurrence rates, time until recurrence, time until progression and pre-operative use of anticoagulants were evaluated. Results: A total of 331 patients comprising 276 males (83%) and 55 females (16%) were included in the study. The mean age of the patients was 64.0±11.8 (28-93) years. The average haematuria duration was 18.5±33.5 (0-260) months. There were 173 (52%), 106 (32%) and 52 (15.7%) patients with cancer stages of Ta, T1 and T2, respectively. The average follow-up time was 54.0±41.8 (1-268) months. The frequency of haematuria was significantly higher in patients with muscle-invasive bladder cancers than in those with superficial bladder cancers (p=0.010). Similarly, patients with tumour diameter >3 cm reported significantly higher frequency of haematuria than in those with tumour diameter <3 cm (p=0.045). Five patients exclude from study because they did not attend their follow-up. During follow-up recurrences were seen in 89 (32.3%) out of 326 patients, while 237 (72.7%) patients did have any recurrences. Disease progression was reported in 28 (8.5%) patients. The average time periods until recurrence and progression were 25.8±34.7 months and 27.1±34.9 (1-144) months, respectively. Conclusion: We found a significant difference between the frequency of haematuria in patients with muscle-invasive cancers and those with superficial cancers. Also, we found a negative correlation between smoking and the time until recurrence in patients with macroscopic haematuria. No significant relationships were observed between the duration of haematuria and cancer recurrence rates and prognosis.

🔖

Cite This Article

ACİNİKLİ, H., YEŞİLDAL, C., KİRECCİ, S. L., BAYAR, G., ALBAYRAK, A. T., ABDULLAYEV, E., YAVUZSAN, A. H. (2021). Predictive Value of Duration and Frequency of Macroscopic Haematuria for Stage, Prognosis and Recurrence in Bladder Cancer Patients. Üroonkoloji Bülteni, Cilt: 20 - Sayı: 1, 34–39. https://ajindex.com/articles/401905

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130
  2. Zorlu F, Eser S, Fidaner C. İzmir ilinde ürogenital kanserlerin insidans hızları. Üroonkoloji Bülteni 2004;1:2-9
  3. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010;60:244-272
  4. Jones JS. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). Campbell-Walsh Urology 2007;3:9
  5. Jichlinski P, Leisinger HJ. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist. Urol Int 2005;74:97-101
  6. Bubendorf L. Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma–FISHing for the right catch. Acta Cytol 2011;55:113-119
  7. Khadra M, Pickard RS, Charlton M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000;163:524-527
  8. Mariani A, Mariani MC, Macchioni C, et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989;141:350-355
  9. Grossfeld GD, Litwin MS, Wolf JS Jr, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and followup. Urology 2001;57:604-610
  10. Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N Engl J Med 2003;348:2330-2338
  11. Mohr DN, Offord KP, Owen RA, Melton LJ. Asymptomatic microhematuria and urologic disease: a population-based study. JAMA 1986;256:224-229
  12. Edwards TJ, Dickinson AJ, Natale S, et al. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int 2006;97:301-305; discussion 305
  13. Gandrup KL, Løgager VB, Bretlau T, et al. Diagnosis of bladder tumors in patients with macroscopic haematuria: a prospective comparison of split-bolus computed tomography urography, magnetic resonance urography and flexible cystoscopy. Scand J Urol 2015;49:224-229
  14. Sutton JM. Evaluation of hematuria in adults. JAMA 1990;263:2475-2480
  15. Gore JL, Lai J, Setodji CM, et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 2009;115:988-996
  16. Wallace D, Bryan RT, Dunn JA, et al. Delay and survival in bladder